Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06152042 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
A Phase 2 study, sponsored by Biomea Fusion.
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT06152042: Clinical Trial Phase 2 study, sponsored by Biomea Fusion.
NCT06152042 is a Phase 2 study that was terminated before completion, run by Biomea Fusion. The registered enrollment target is 37 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06152042, a Phase 2 study, was terminated before completion, sponsored by Biomea Fusion.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.
Primary Outcome
Mean change from baseline in stimulated C-peptide AUC.
Interventions
- DRUG BMF-219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2025-07-18 |
| Phase | Phase 2 |
Why NCT06152042 stopped before completion
NCT06152042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 1 intervention - of which BMF-219 is the first listed.
NCT06152042 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06152042 about?
NCT06152042 is a clinical study titled "Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus". Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.
What is the current status of trial NCT06152042?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2023-12-28. Estimated completion is 2025-07-18.
What interventions are being tested in trial NCT06152042?
The interventions under investigation include: BMF-219 (DRUG).
Who is sponsoring clinical trial NCT06152042?
This trial is sponsored by Biomea Fusion, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06152042's enrollment target sits among peer trials
37 1484th of 2000 higher than 505 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI